Bayer’s Washington Setback Piles Pressure on Anderson’s Turnaround Narrative

The US House of Representatives has sent the Farm Bill to the Senate without the preemption clause Bayer had lobbied for, leaving the German conglomerate exposed to a patchwork of state-level glyphosate litigation. The provision would have made EPA pesticide classifications legally binding nationwide, creating uniform warning requirements and potentially capping the company’s liability exposure. Instead, plaintiffs can continue seeking damages under individual state laws — a status quo that keeps the legal overhang firmly in place.

The stock initially dipped on the news Monday but steadied at €37.80 by Tuesday. Over the past week, the shares have added roughly 4.5%, while the 12-month picture shows a gain of nearly 58% from a deeply depressed base. The longer-term rally reflects growing investor optimism about CEO Bill Anderson’s restructuring push, but the Washington setback underscores how fragile that confidence remains.

The €2 Billion Efficiency Target Meets Reality

Anderson’s “Dynamic Shared Ownership” overhaul has already eliminated six layers of management and slashed executive positions. The goal is sustainable annual savings of €2 billion by the end of 2026. Major shareholders, including DWS and Union Investment, have praised the operational recovery at the recent annual general meeting, but the tone from Deka’s Ingo Speich was blunt: “2026 will be the year of decision. Not just for Bayer, but for you.”

The first-quarter results, due May 12 at 07:30 CET, will provide the first hard evidence of whether the restructuring is translating into measurable financial improvement. CFO Wolfgang Nickl will join Anderson in presenting the numbers, and the call is expected to focus heavily on legal provisions and the strategy for managing US liability risks.

Should investors sell immediately? Or is it worth buying Bayer?

Mixed Signals from the Operating Units

Early indicators for the opening quarter paint an uneven picture. Crop Science, the agricultural division, posted revenue of €4.9 billion, but lower fungicide volumes dragged sales down 5%. Pharmaceuticals, which contributes nearly half of group revenue, provided a counterweight. Growth drivers such as the kidney drug Kerendia have been gaining traction, and Bayer recently secured Japanese approval for the new MRI contrast agent Ambelvist, as well as an additional indication for the eye drug Eylea.

The pharma pipeline is showing signs of life, but the agricultural headwind and the unresolved legal situation leave the group’s earnings trajectory uncertain. Analysts see a consensus fair value of €42.00 per share and forecast earnings per share of €4.25 for 2026. Management has guided for full-year adjusted EPS between €4.30 and €4.80.

Debt and Cash Flow Remain the Achilles’ Heel

Despite operational progress, the balance sheet remains under strain. Bayer expects negative free cash flow of up to €2.5 billion this year, and net debt could climb to around €33 billion. To preserve cash, the company paid only the statutory minimum dividend of €0.11 per share in late April — a stark reminder of the financial drag from the glyphosate legacy.

Bayer at a turning point? This analysis reveals what investors need to know now.

The stock currently trades at €37.84, comfortably above its 200-day moving average. However, the relative strength index stands at 77, signaling a short-term overbought condition. The upcoming quarterly report will need to justify that elevated valuation with solid fundamentals.

For Anderson, the May 12 presentation is more than a routine earnings release. It is the moment when the narrative of a turnaround must meet the numbers. The Farm Bill failure in Washington only raises the stakes.

Ad

Bayer Stock: New Analysis - 6 May

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER’S | boerse | 69284130 |